Stoneridge Investment Partners LLC cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.6% during the third quarter, Holdings Channel reports. The institutional investor owned 16,589 shares of the company’s stock after selling 4,577 shares during the period. Stoneridge Investment Partners LLC’s holdings in Zimmer Biomet Holdings were worth $2,157,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. UMB Bank N A MO increased its position in shares of Zimmer Biomet Holdings by 183.8% in the second quarter. UMB Bank N A MO now owns 24,307 shares of the company’s stock worth $2,926,000 after buying an additional 15,742 shares in the last quarter. Atalanta Sosnoff Capital LLC acquired a new stake in shares of Zimmer Biomet Holdings during the second quarter worth approximately $42,984,000. Pitcairn Co. boosted its stake in shares of Zimmer Biomet Holdings by 221.9% in the second quarter. Pitcairn Co. now owns 6,889 shares of the company’s stock worth $829,000 after buying an additional 4,749 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Zimmer Biomet Holdings by 9.2% in the second quarter. Louisiana State Employees Retirement System now owns 13,100 shares of the company’s stock worth $1,577,000 after buying an additional 1,100 shares during the last quarter. Finally, Cornerstone Advisors Inc. boosted its stake in shares of Zimmer Biomet Holdings by 2.8% in the second quarter. Cornerstone Advisors Inc. now owns 2,073 shares of the company’s stock worth $250,000 after buying an additional 57 shares during the last quarter. Institutional investors and hedge funds own 84.98% of the company’s stock.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up 0.95% on Wednesday, reaching $114.75. 2,484,963 shares of the company traded hands. Zimmer Biomet Holdings, Inc. has a 52-week low of $88.27 and a 52-week high of $133.21. The stock has a market capitalization of $22.98 billion, a price-to-earnings ratio of 64.25 and a beta of 1.23. The firm has a 50 day moving average price of $103.53 and a 200 day moving average price of $118.32.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.79. The firm had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.64 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post $7.92 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Shareholders of record on Friday, December 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.84%. Zimmer Biomet Holdings’s payout ratio is presently 75.00%.

ILLEGAL ACTIVITY WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this piece can be viewed at http://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-shares-sold-by-stoneridge-investment-partners-llc/1056850.html.

ZBH has been the topic of a number of research reports. Jefferies Group lowered their price objective on shares of Zimmer Biomet Holdings from $150.00 to $129.00 and set a “buy” rating on the stock in a research note on Tuesday, November 1st. Canaccord Genuity reissued a “buy” rating and issued a $130.00 price objective (down from $150.00) on shares of Zimmer Biomet Holdings in a research note on Monday, October 31st. Argus reissued a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet Holdings in a research note on Thursday, September 22nd. RBC Capital Markets set a $143.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Wednesday, September 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $148.00 price objective on shares of Zimmer Biomet Holdings in a research note on Thursday, December 15th. Four investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $130.45.

In other Zimmer Biomet Holdings news, insider David A. Jr. Nolan sold 5,050 shares of the business’s stock in a transaction dated Friday, December 2nd. The stock was sold at an average price of $101.11, for a total transaction of $510,605.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.